Correction to: Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients

Clin Exp Nephrol. 2019 Sep;23(9):1173. doi: 10.1007/s10157-019-01758-x.

Evocalcet Study Group:
Yoshimitsu Hayashi, Hidetomo Nakamoto, Shoji Koga, Ichiro Okido, Minoru Kubota, Fumihiko Koiwa, Masahiro Takeda, Terumasa Hayashi, Makoto Hiramatsu, Hideki Kawanishi, Hidetoshi Kanai, Sakuya Ito, Kazuhiko Tsuruya, Koji Mitsuiki, Hirofumi Ikeda

¹ Department of Nephrology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8521, Japan. tsuruya@naramed-u.ac.jp.
² R&D Division, Kyowa Hakko Kirin Co., Ltd., 1-9-2 Otemachi, Chiyoda-ku, Tokyo, 100-0004, Japan.
³ Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
⁴ Division of Nephrology, Department of Medicine, Showa University School of Medicine, Namics 301, 4-24-51 Takanawa, Minato-ku, Tokyo, 108-0074, Japan.

Abstract

The article "Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients.